Fhit loss-associated initiation and progression of neoplasia in vitro

Jenna R. Karras,1 Morgan S. Schrock,1,4 Bahadir Batar,1,4 Jie Zhang,2 Krista La Perle,3 Teresa Druck1 and Kay Huebner1

Departments of 1Cancer Biology and Genetics, 2Biomedical Informatics, Ohio State University Wexner Medical Center, Columbus, Ohio; 3Department of Veterinary Biosciences, College of Veterinary Medicine, Ohio State University, Columbus, Ohio, USA

Key words
Cell transformation, common fragile site, genome instability, kidney cell lines, tumorigenicity

Correspondence
Kay Huebner, Department of Cancer Biology and Genetics, The Biomedical Research Tower, Room 916, 460 W. 12th Avenue, Columbus, OH 43210, USA. Tel: +1-614-292-4850; Fax: +1-614-688-8675; E-mail: kay.huebner@osumc.edu

†These authors contributed equally to this work.

Funding Information
Ohio State University Comprehensive Cancer Center; The Scientific and Technological Research Council of Turkey; National Cancer Institute (CA120516, CA166905).

Received May 30, 2016; Revised August 5, 2016; Accepted August 9, 2016

Cancer Sci 107 (2016) 1590–1598
doi: 10.1111/cas.13032

Chromosome fragile sites are among the most frequently deleted loci in cancer.(1) The fragile gene, FHit, was identified by the Huebner laboratory(2–4) at a locus that is inactivated in >50% of human cancers. (4,5) FHit locus deletions are among the first genetic changes detected in human preneoplastic lesions. (6,7) Many biological functions are altered by Fhit loss in cancers: decreased apoptosis, (8) increased epithelial–mesenchymal transition (EMT), (9,10) increased resistance to genotoxic agents, (11) altered production of reactive oxygen species, (12) and ongoing genome instability. (13,14) However, the direct mechanisms through which the Fhit protein affects these functions has remained elusive. Lack of a known mechanism of action has slowed general acceptance of a role for Fhit in tumor suppression, despite strong evidence of Fhit association with multiple cancer-associated functions. This skepticism has hindered consideration of Fhit-associated therapeutic targets for the many Fhit-deficient human cancers. For example, the accumulation of genome mutations due to Fhit loss and the ability to stop the accumulation of genome damage by thymidine supplementation (13) hint at possible preneoplasia prevention strategies. In addition, Fhit loss-induced DNA damage creates optimal single-stranded DNA substrates for the APOBEC3B enzyme (a cytidine deaminase that converts cytosines to uracils in single-stranded DNA), illustrating a key role for Fhit loss (15) in hypermutation genotypes observed in most common cancers, a major source of cancer-associated genetic heterogeneity. (16) The APOBEC3B enzyme, which causes hypermutations selectively in Fhit-deficient cells, is likely a critical diagnostic and therapeutic target. (16)

The purpose of the current study was to show that Fhit deficiency supports neoplastic progression. We followed expression changes from establishment, through proliferation in the face of selective pressures, to transformation and nascent neoplastic changes, in epithelial cells from Fhit knockout and wild-type mice. We have observed that Fhit loss is followed by genomic and functional changes in response to selective pressures that allow survival of clonally expanded populations, supporting the conclusion that Fhit loss-induced genome instability enables selection for transformation and neoplastic progression.

Materials and Methods

Ethics statement. Mice were maintained and animal experiments carried out in accord with institutional guidelines established by the Animal Care and Use Committee at Ohio State University (Columbus, OH, USA).

Cell lines and reagents. Mouse kidney cell lines were established by culturing minced mouse kidney tissue from three Fhit+/– C57Bl6 (B6 +/- kd cell lines 1, 2, 3) and three Fhit−/– (B6x129SvJ backcross, >99% B6 at genomic level) (17) 5-week-old mice (−/− kd cell lines 2, 3, 4). After emergence of...
epithelial cells from minced kidney fragments, cells could be subcultured; these epithelial kidney cell lines did not show an obvious crisis phase but rather grew steadily from first subculturing. Early passage +/+ and −/− kidney lines did not show obvious morphological or proliferation differences (Figs S1, S2). However, late passage −/− kidney lines grew more rapidly than +/+ (Fig. S2). RNA, DNA, and protein were isolated at alternate passages. To establish 7, 12-dimethylbenz[a]anthracene (DMBA) surviving (DS) cell lines, late passage (p40) cells were treated with two sequential 24-h, 20-μM DMBA doses, followed by plating and culturing of surviving colonies 8 days post-treatment; +/+ cells did not survive DMBA treatment. To establish nutritionally stressed (NS) cell lines, early passage cells were maintained without replenishing medium for several months, followed by fresh medium and culture of surviving colonies; +/+ cell lines did not survive nutritional stress. The NS cell lines exhibited new morphological features as they transitioned from epithelial to mesenchymal phenotype (Fig. S1). Nutritionally stressed cells also grew to a higher density than +/+ cells (Fig. S2). Some DS and NS cell lines formed colonies in soft agar. Colonies were isolated and replated to establish colony-forming cell lines (Table 1 summarizes cell line characteristics). The mouse cell lines were cultured in MEM with 5% FBS and 100 μg/mL gentamicin. H1299, a human non-small-cell lung carcinoma cell line, was cultured in MEM with 10% FBS and 100 μg/mL gentamicin.

**Immunoblot, soft agar growth, and invasion assays.** Immunoblot was carried out as described. Antisera used and working dilutions are available in Table S1. Soft agar(20) and invasion(21,22) assays were performed as previously described. 

**Ras and Trp53 sequencing, expression plasmid construction, and transient transfection.** F131L and S151R Trp53 cDNAs were amplified from NS1 and NS2 cell lines, respectively, using the following conditions: 94°C for 5 min, 30 cycles at 94°C for 30 s, 54°C for 30 s, 68°C for 2 min, and held at 4°C. Trp53 forward 5'-GCGAAGCTTAGCTGCGATG- GAGGAGTCA-3' and reverse 5'-GCTCTAGACCGGAGTCATAAGAC-3' primers were used. Mutant Trp53 cDNA was cloned into HindIII and XbaI sites of the pReCMV vector (Invitrogen, Carlsbad, CA, USA) and recombinant clones were sequenced as previously described. Primers used are available in Table S2.

**Microarray expression profiles.** Total RNA (+/−kdd p14, −/− kdd p48, NS3 colony p13) was isolated using RNeasy Mini Kit (Qiagen, Hilden, Germany). RNA integrity was assessed using the Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA, USA). A 100-ng aliquot of total RNA was linearly amplified. Then 5.5 μg cDNA was labeled and fragmented using the GeneChip WT PLUS reagent kit (Affymetrix, Santa Clara, CA, USA) following the manufacturer’s instructions. Labeled cDNA targets were hybridized to the Affymetrix Mouse GeneChip Mouse Transcriptome Array 24 for 16 h at 45°C, washed, and stained using the Fluidics Station 450 (Ohio State University Medical Center Shared Facility, Columbus, OH, USA) and scanned using the GeneChip Scanner 3000 (Ohio State University Medical Center Shared Facility, Columbus, OH, USA). For gene expression analysis, arrays were normalized using the RMA algorithm in Expression Console and comparisons made in Transcriptome Analysis Console (Affymetrix). Microarray data have been deposited in the NCBI Gene Expression Omnibus (accession # not yet available).

**Tumorigenicity and metastasis assays.** Athymic nude mice were obtained from the Target Validation Shared Resource of the Ohio State University Comprehensive Cancer Center and maintained on an outbred background. Original breeders (strain#553 and #554) came from the NCI Frederick facility. Fhit+/+(1 x 10^7) and NS3 colony (1 x 10^7) cells in 100 μL PBS were injected s.c. into the right flank, four mice per cell line, in the first round of injections. Subsequent injections used 5 x 10^6 (Fhit+/+, NS1 colony, NS3 colony, NS3T) cells in a total of 20 mice (six female, 14 male). Mice were monitored twice weekly for tumor formation up to 6 months after inoculation. For assessment of metastatic growth, NS3T cells were injected into seven mice (two female, five male). Briefly, 5 x 10^6 (or 2 x 10^6) cells resuspended in 150 μL PBS were tail-vein injected. Mice were monitored twice weekly up to 2 months post-inoculation and sacrificed up to 8 weeks post-injections. Inducible clones B28 and B29 were treated with doxycycline (1 μg/mL) 48 h before harvesting 5 x 10^6 cells in 150 μL PBS for s.c. injections into the right flank of 18 male mice. Mice received sucrose (30%) or doxycycline water (1.2 mg/mL) beginning 12 days prior to injections with water replacement every 6 days.

**Histopathology and immunohistochemistry.** Subcutaneous tumors were measured and fixed in 10% neutral buffered formalin; lungs were insufflated with 10% neutral buffered formalin prior to immersion fixation. Tissues were processed by routine methods and embedded in paraffin. Sections (4 μm) were stained with HE or deparaffinized and hydrated for immunohistochemistry, carried out as previously described. Slides were evaluated with an Olympus BX5 light

---

**Table 1. Derivation of mouse kidney cell lines**

| Cell line | Derived from | Agar colonies |
|-----------|--------------|---------------|
| Fhit +/+  |              |               |
| Subcultured |              |               |
| +/− kdd1 | ♂ ms 3451 | No            |
| +/− kdd2 | ♂ ms 3452 | No            |
| +/− kdd3 | ♂ ms 3453 | No            |
| Fhit −/−  |              |               |
| Subcultured |              |               |
| −/− kdd1 | ♀ ms 3454 | No            |
| −/− kdd2 | ♀ ms 3455 | No            |
| −/− kdd3 | ♀ ms 3456 | No            |
| Nutrionally stressed |              |               |
| NS1     | −/− kdd p3| Yes           |
| NS2     | −/− kdd p2| No            |
| NS3     | −/− kdd p5| Yes           |
| NS4     | −/− kdd p8| No            |
| DMBA survivors |          |               |
| DS2     | −/− kdd p38| Yes           |
| DS3     | −/− kdd p40| No            |
| DS4     | −/− kdd p41| No            |
| Colony forming |        |               |
| NS1 colony | ♂ NS1 p24| Yes           |
| NS3 colony | ♂ NS3 p13| Yes           |
| DS2 colony | ♂ DS2 p10| Yes           |
| DS3 colony | ♂ DS3 p15| Yes           |

Cell lines were established from culture of single kidneys from three Fhit+/+ C57Bl6 and three Fhit−/− (B6x129SvJ backcross) mice at 5 weeks of age. Nutritionally stressed (NS) cell lines were isolated from early passage −/− kdd lines and −/− kdd3 lines after maintenance without replenishing medium for 3 months, followed by fresh medium and continued subculture. 7,12-Dimethylbenz[a]anthracene (DMBA) survivor (DS) cell lines were established after treatment with 20 μM DMBA. Colony-forming cell lines were established after excision and plating of soft agar colonies.
microscope with attached DP25 digital camera (B & B Microscopes, Ohio State University Veterinary College Shared Facility, Columbus, OH, USA) by a comparative pathologist board certified by the American College of Veterinary Pathologists. The antisera used and the working dilutions are available in Table S1.

Lentiviral vector construction. Wild-type human FHIT cDNA was amplified from previously constructed plasmid (24) using the following conditions: 95°C for 3 min, 30 cycles at 98°C for 10 s, 55°C for 15 s, 72°C for 5 s, and held at 4°C. FHIT forward 5'-CCCTCGTAAAGAATTCATGTCGTTCAGAT-3' and reverse 5'-GAGGTTGGTCTGGATCCTCACTGAAAGTA-3' primers were used. The cDNA was cloned into EcoRI and BamHI sites of the pLVX-TetOne-Puro vector (Clontech, Mountain View, CA, USA). This vector allows transgene expression by the doxycycline-inducible TRE3G promoter. Transgene expression on doxycycline induction was assessed by immunoblot using anti-Fhit polyclonal serum.

Generation of inducible Fhit transfectants. The recombinant plasmid (pLVX-FHIT) was transfected into NS3T mouse kidney cells using Xfect buffer and polymer reagents (Clontech). Mouse kidney cells were plated at a density of 4 × 10^5 cells per 60-mm dish and cultured in normal growth medium. Transfections were with 5 μg plasmid DNA diluted with 90 μL Xfect buffer before addition of 1.5 μL Xfect polymer. The solution was incubated for 10 min at room temperature. Cells were overlaid with plasmid DNA/polymer solution and incubated for 24 h. Stable clones were selected in puromycin (2 μg/mL) and tested for doxycycline inducible Fhit expression.

Results

In vitro model of Fhit loss-associated neoplastic progression. To create an in vitro model for Fhit-deficient cell transformation, we established mouse kidney epithelial cell lines, three from Fhit+/+ (+/+kd1, +/+kd2, and +/+kd3) and three from Fhit knockout (−/−kd2, −/−kd3, and −/−kd4), post-weaning mice. These cell lines were subcultured through tissue culture passage (p50) and accumulating alterations examined. The initial cell cultures were also used to generate DS and NS survivor cell lines. Fhit+/+ cell lines did not survive these stresses. Thus, there were a total of three Fhit+/+ cell lines and 14 Fhit−/− cell lines, for which different selective pressures were applied (see Table 1 for cell line summary).

Fhit−/− cells show alterations in apoptotic and EMT signal pathways. To follow the evolution of cells from the benign to malignant state in vitro, we assessed changes in proteins in signal pathways that are frequently altered in cancers, beginning with the Trp53/p21 and EMT pathways. In assessing the untransduced +/+ and −/− kidney cell lines, a reduction in Trp53 protein expression was observed in late-passage −/−−kd3 along with a decrease in its downstream target p21 (Fig. 1a). Trp53/p21 pathway changes were not observed in DS cell lines (Fig. 1b). Striking changes in Trp53/p21 pathway proteins occurred in the NS lines; all four NS lines displayed Trp53 protein expression but lacked p21 expression, suggesting that these cell lines harbor mutated Trp53 genes, selected for survival of nutritional stress (Fig. 1c). Indeed, absence of p21 expression is due to mutation in the DNA binding domain of the Trp53 protein. All NS lines showed C to G base substitutions, changing a phenylalanine to a leucine at amino acid position 131 (F131L) in NS1, NS3, and NS4 lines, and changing a serine to an arginine at amino acid position 151 (S151R) in NS2 (Fig. S3). Mutations in the Trp53 DNA binding domain can result in faulty transcription of the CDKN1A gene encoding p21 protein. To confirm that p21 protein is downregulated due to Trp53 mutation, we transfected NS lines with wild-type and mutant Trp53 plasmids to determine if p21 expression could be restored. Re-expression of p21 was observed in both NS1 and NS2 cells that were transfected with wild-type Trp53, but not when transfected with F131L or S151R Trp53 mutants (Fig. 1d). Although DS lines did not exhibit changes in the Trp53/p21 pathway, increased expression of the pro-survival protein, survivin, was observed (Fig. 1e). To discern if Fhit−/− cells have acquired protumorigenic activities, we tracked expression of vimentin, a marker of the mesenchymal phenotype and a hallmark of EMT. All NS lines showed robust expression of vimentin (Fig. 1c), suggesting these cells have undergone EMT and...
possess migratory abilities. Tables S3 and S4 display expression patterns of other proteins tested.

**Fhit loss-associated cell transformation.** Because protein expression studies provided evidence of *in vitro* transformation in Fhit−/− cells, we compared biological features of +/+ and −/− kd cell lines, by measuring the effect of Fhit deficiency on anchorage-independent growth in soft agar. After 24 days of culture in soft agar, some cells of NS1 and NS3 showed anchorage-independent growth, producing 15 and 13 colonies, respectively (Fig. 2a). Additionally, some cells of DS cell lines DS2 and DS3 formed large colonies (Fig. 2a,b, representative agar colonies at day 24). No colony formation was observed for any of the +/+ and untested −/− kd cell lines. Moreover, after collection of agar colonies and propagation, we reassessed one colony line from each group for colony formation potential. Each new colony cell line showed rapid anchorage-independent growth and formed increased numbers of agar colonies (Fig. 2c). Thus, subpopulations of cells in these lines on exposure to exogenous stress showed anchorage-independent growth and colony formation, characteristics of transformed cells. Western blot analysis showed that Trp53 overexpression and loss of p21 had also occurred in NS1 and NS3 colony cell lines, indicating that the Trp53 missense mutation acquired in NS1 and NS3 was maintained in these colony-forming lines (Fig. 2d). The DS2 colony line expressed normal Trp53/p21 pathway expression, whereas DS3 colony cells had lost Trp53 protein expression, resulting in downregulation of p21 expression, as observed in the −/− kd3 parent cell line. Furthermore, the NS3 colony line showed a dramatic increase in vimentin expression. The NS1 colony line displayed a lower level of vimentin expression; DS2 and DS3 colonies did not express vimentin (Fig. 2d). An invasion assay through a basement matrix-coated membrane was carried out to determine if colony-forming cell lines also showed invasive capacity; the NS3 colony line had significant invasive ability versus +/+ controls (*P* = 0.01) (Fig. 2e). The NS1 colony line showed increased invasive potential versus a +/+ control cell line, in accord with the low level increase in vimentin expression observed (Fig. 2d,e).

**Classification of genes with altered transcription in a Fhit−/− NS cell line.** To further characterize signal pathway alterations that contribute to Fhit loss-supported cellular transformation, we examined signal pathways identified by mRNA expression profiling. Ingenuity Pathway Analysis (IPA) was used to analyze the differentially expressed genes in the *in vitro* invasive NS3 colony cell line relative to its non-invasive progenitor −/− kd3. Using a significance cut-off of *P* < 0.05 and a fold-change cut-off of 4, there were 432 differentially expressed genes in NS3 colony cells versus −/− kd3. An IPA core analysis was carried out to classify this dataset into top biological functions and canonical pathways (Fig. 3a,b), several of which revolve around DNA replication, cell cycle control, and DNA repair. An invasion-associated network was constructed to focus on specific genes influencing the invasive phenotype of this cell line (Fig. 3c). Relative to the −/− kd3 parent, the NS3 colony cell line displayed 35-fold downregulation of E-cadherin (*Cdh1*), an epithelial marker, and 55-fold upregulation of vimentin (*Vim*). Upregulation of transcription factors known to induce EMT, such as *Zeb1*, *Snai2*, and *Foxm1* is also observed in NS3 colony cells. (25–28) Furthermore, genes involved in regulating cell–cell contacts and cell junction integrity are differentially expressed in favor of facilitating the EMT process, confirming that NS3 colony cells are gaining invasive properties. Additionally, a network analysis of DNA damage response-associated genes (Fig. 3d) identified genes important for replication fork progression such as *Top2a*, *Mcm10*, *Lig1*, and * Rad51* that are upregulated, possibly participating in maintaining increased proliferative signaling. *Chek1*, a gene responsible for coordinating the DNA damage response, and DNA double-strand break repair proteins *Brcal* and *Rad51* are also upregulated, suggesting enhanced DNA damage repair in NS3 colony cells. No expression changes were observed for *Myc*, *Raf*, *Mek*, *Erk*, *Erbb2*, *Egf*, or *Ras*. Sequence analysis of *Kras*, *Hras*, and *Nras* cDNAs from NS cell RNA detected only wild-type sequence at hotspot regions in all NS lines. In the “cyclins/cell cycle regulation” canonical pathway, cyclins *Ccne1*, *Ccne2*, and *Ccnb1* were upregulated 2.78-, 5.29-, and 10.4-fold, respectively, in NS3 colony cells versus +/+ controls (*P* = 0.01) (Fig. 3d). The NS3 T cells show tumorigenic and metastatic potential. To assess *in vivo* behavior, we injected the *in vitro* invasive
colony cell lines s.c. into 6-week-old nude mice and observed animals weekly for appearance of tumors. The NS1 colony formed tumors in male mice by day 125. Of two male and two female mice injected, the NS3 colony formed tumors at sites on the shoulder and flank in one male mouse by day 133. Both sites developed sizable tumors by day 151 (flank tumor, 15 ± 912 mm; shoulder nodules, 5 ± 5 mm and 3 ± 5 mm) that showed a mesenchymal spindle cell neoplasm phenotype (Fig. S4). Of four mice injected with +/−kd3 p15, none developed tumors by day 200. NS3 tumors were excised for histopathology, the NS3 flank tumor was cultured in vitro, and the tumor outgrowth cell line was designated NS3T. A second round of s.c. injections was performed to determine whether the cultured NS3T cells showed increased tumorigenicity. NS3T p10 and control +/−kd3 p16 cells were injected into flanks of four nude mice each (two females and two males). Both male mice injected with NS3T cells formed tumors within 12 days, with mean tumor size ∼100.5 mm³ by 19 days (Fig. 4a). Neither the female mice nor the +/−kd3-injected mice developed tumors and were sacrificed at day 60. The results suggested that tumor formation was biased towards male mice, possibly because the androgen-receptor is expressed in the NS3 cells as noted in the expression array profile, and the initial cell line was derived from a male mouse kidney; s.c. injections using later passage NS3 colony cells resulted in 100% tumor incidence in female mice. A final round of NS3T cells was injected s.c. into five male nude mice and four of them developed tumors by 10 days (Fig. 4b). See the summary of tumor incidence in Table 2. Two of these s.c. tumors were further characterized for an EMT phenotype by assessment of expression of vimentin, E-cadherin, and cytokeratin using immunohistochemistry. In accord with our transcriptome and Western blot analysis, these tumors were strongly immunoreactive for vimentin and immunonegative for cytokeratin and E-cadherin (Fig. 4c).

The metastatic capacity of the NS3T cells was evaluated by tail vein injection in male and female nude mice. Histological examination showed lung micrometastases in 3/5 male and 2/2 female mice. Lung tumors were more abundant (up to five nodules/lung) and larger in male mice sacrificed 43 days post-injection, whereas both female mice showed a small, single neoplastic nodule within one lung lobe when sacrificed 58 days post-injection. Neoplastic cells were
distributed within the alveolar parenchyma, around blood vessels and bronchioles, subpleurally or intravascularly. Lung tumors of one male were characterized by immunohistochemistry as performed for primary s.c. tumors. Neoplastic cells in the lung were strongly immunoreactive for vimentin and immunonegative for cytokeratin and E-cadherin, in contrast to normal bronchiolar epithelium (Fig. 4c). Thus, the alterations that occurred in vitro contributed to in vivo tumorigenicity and metastasis.

Induced Fhit expression delays tumor onset in vivo. To confirm that Fhit loss is responsible for tumor initiation in vitro, we created two stable NS3T clones, B28 and B29, that were doxycycline-inducible for Fhit expression. For both clones, we observed no differences in soft agar colony growth, in vitro
invasive potential, or final tumor volumes in vivo between Fhit-deficient and Fhit-induced cells (Fig. 4d). However, clone B28 showed a significantly (P = 0.0001) delayed onset of tumor formation in mice induced for Fhit expression by doxycycline water. All B28 control mice developed tumors by day 13, whereas tumors did not start to appear until day 16 in the Fhit-induced mice (Fig. 4e). Clone B29 did not display the same effect on tumor latency following Fhit induction (Fig. 4e). Western blot analysis of the clonal cell lysates revealed that 48-h doxycycline treatment of clone B29 cells caused ~10-fold lower level induction of Fhit protein versus clone B28 (Fig. 4f), suggesting that robust Fhit expression is necessary for delaying tumor onset. As there is no selection for retention of the inducible plasmid in the in vivo environment, loss of Fhit plasmid and Fhit expression likely explains eventual tumor development by both clones.

Discussion

The translational research world places substantial focus on the late stages of cancer and identification of specific cancer driver genes. But largely because of the extensive genome instability of neoplastic cells underlying the extreme clonal heterogeneity of metastatic cancer, treatment frequently fails due to relapse and therapy resistance. Thus, the idea of concentrating on the biology of premalignancy to advance prevention and early diagnosis is gaining interest. Kensler et al. (29) have proposed a PreCancer Genome Atlas initiative for solid tumors of epithelial origin to investigate the molecular alterations associated with premalignant lesions. Alterations of the FHit gene, straddling a common fragile site, occur in the neoplastic lesions preceding development of many human cancers.

Point mutations and small insertions/deletions have long been a focus in tumor sequencing; however, recent studies have suggested that genome structural variants, such as deletions and translocations, may play a larger role in cancer progression than previously thought. In 2015, investigators examined the contribution of recurrent structural variations in the progression of pancreatic cancer. Analysis of 24 ductal pancreatic adenocarcinomas revealed that the FHit gene is the second most frequently altered gene, with deletions observed in 50% of pancreatic adenocarcinoma tumors that resulted in reduction of Fhit protein expression. (30) Another study used whole genome sequencing to fully characterize the genomic landscape of gastric and esophageal tumors. Compared to matched normal blood samples, recurrent deletions at the FHit locus were identified in 46% of tumors. (31) Our laboratory has shown that such alterations at the FHit locus can lead to loss of Fhit protein expression, causing mild replication stress through TK1 downregulation and subsequent dNTP imbalance. (13)

The current study followed in vitro cellular alterations associated with Fhit absence to illustrate that loss of Fhit genome caretaker function supports in vitro tumorigenic progression. We showed that Fhit loss provides a survival and expansion advantage when selective pressures are applied, enabling selection for neoplastic properties. As proof that Fhit loss provides a survival advantage, all three Fhit+/+ cell lines did not survive exogenous stress, whereas all Fhit−/− cell lines had surviving colonies, revealing that Fhit loss-associated genome instability allows a fraction of Fhit−/− cells to survive these stresses, even at early tissue culture passages. Furthermore, in contrast to Fhit+/+ cells, we showed that loss of Fhit, combined with stressful exposures, leads to alterations in apoptotic and EMT signaling pathways and oncogene activation. These alterations allow for transformation, selective clonal expansion, and development of invasive properties in vitro and tumor formation and metastasis in vivo. Finally, induction of exogenous wild-type Fhit protein delayed the onset of tumor formation in vivo. The documentation of frequent FHIT allele losses in precancerous lesions, in combination with our demonstration that loss of Fhit expression supports neoplastic and neoplastic clonal expansion, reveals Fhit loss as a driver of neoplastic progression.

Table 2. Summary of tumorigenicity data in mouse kidney cell lines

| Cell line | Sex of host | Route | Days post-injection | Tumor frequency | Comments |
|-----------|-------------|-------|--------------------|-----------------|----------|
| NS1 colony | 2♂ | s.c. | 125 | 2/2 |          |
| NS3 colony | 2♂ | s.c. | 200 | 1/2 |          |
| 2♀ | s.c. | 200 | 0/2 | Early passage (p14) |          |
| 2♂ | s.c. | 200 | 2/2 | Late passage (p27) |          |
| NS3T | 7♀ | s.c. | 60 | 6/7 |          |
| 2♂ | s.c. | 60 | 0/2 |          |          |
| NS3T | 5♂ | i.v. | 45 | 3/5 |          |
| 2♂ | i.v. | 58 | 2/2 |          |          |
| +/+ kd3 | 3♀ | s.c. | 125 | 0/3 | Control for NS1 colony injections |
| +/+ kd3 | 2♂ | s.c. | 200 | 0/2 | Control for NS3 colony injections |
| 2♂ | s.c. | 200 | 0/2 | Control for NS3 colony injections |
| +/+ kd3 | 2♂ | s.c. | 60 | 0/2 | Control for NS3T injections |
| 2♂ | s.c. | 60 | 0/2 | Control for NS3T injections |

Initial studies showed that NS3 colony cells did not form tumors in female mice, possibly due to expression of androgen receptor. Thus, NS3 colony tumor incidence was 50% in male mice. Late-passage NS3 colony tumor incidence of 100% in female mice suggests loss of androgen receptor expression. The NS3T tumor incidence was 85% (P = 0.0109).

© 2016 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.
preclinical research and may inspire additional approaches to inhibit genome instability.

In summary, this study demonstrates that Fhit-deficient cells are more likely to acquire cancer-promoting mutations. Through selective pressures to survive, activating mutations in oncogenes or inactivating mutations in tumor suppressor genes expedite the cellular transformation process. We conclude that in preneoplastic lesions of human tissues, losing Fhit provides a selective advantage for transformation and cancer progression. The significance of Fhit loss as an alteration that lies at the core of cancer initiation and progression should be exploited as a prevention or therapeutic strategy due to its relevance in >50% of human cancers.

Acknowledgments

This work was supported by: Ohio State University Comprehensive Cancer Center (OSUCCC) Pelotonia Graduate Student (to M.S.S.) and Postdoctoral (to B.B.) Fellowships; a fellowship from The Scientific and Technological Research Council of Turkey (TUBITAK to B.B.); and NCI grants CA120516 (to K.H.) and CA166905 (J.R.K.-PI: C.M. Croce). We acknowledge The Target Validation Shared Resource at OSUCCC for nude mice, the Genomics and Campus Microscopy and Imaging Facility, and Mouse Phenotyping shared resources.

Disclosure Statement

The authors have no conflict of interest.

Supporting Information

Additional Supporting Information may be found online in the supporting information tab for this article.

Table S1. Antiseras used, dilutions and applications.

Table S2. Primers used for gene amplification. Note: Trp53 and Nras coding regions were amplified and sequenced from cDNA; genomic DNA was used to amplify and sequence exons 1, 2, and 3 of Kras and exons 1, 2 of Hras.

References

1 Biguell GR, Greenman CD, Davies H et al. Signatures of mutation and selection in the cancer genome. Nature 2010; 463: 893–8.
2 Otta M, Inoue H, Cottecelli MG et al. The Fhit gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digest tract cancers. Cell 1996; 84: 587–97.
3 Karras JR, Paisie CA, Huebner K. Replicative stress and the FHit gene: roles in tumor suppression, genome stability and prevention of carcinogene-
sis. Cancers (Basel) 2014; 6: 1208–19.
4 Pichiorri F, Palumbo T, Suh SS et al. Fhit tumor suppressor: guardian of the preneoplastic genome. Future Oncol 2008; 4: 815–24.
5 Waters CE, Saldivar JC, Hosseini SA et al. The FHit gene product: tumor suppressor and genome “caretaker”. Cell Mol Life Sci 2014; 71: 4577–87.
6 Gorgoulis VG, Vassiliou LV, Karakaidos P et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 2005; 434: 907–13.
7 Bartkova J, Horejsi Z, Koed K et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 2005; 434: 864–70.
8 Sardi L, Accornero P, Tornielli S et al. The tumor-suppressor gene FHT is involved in the regulation of apoptosis and in cell cycle control. Proc Natl Acad Sci USA 1999; 96: 8489–92.
9 Joannes A, Grelet S, Duca L et al. FHit regulates EMT targets through an EGFR/Src/ERK/Slug signaling axis in human bronchial cells. Cancer Res 2004; 64: 1669–77.
10 Ottery M, Han SY, Druck T et al. Fhit-deficient normal and cancer cells are mitomycin C and UVC resistant. Br J Cancer 2004; 91: 1669–77.
11 Okumura H, Iishi H, Pichiorri F et al. Fragile gene product, Fhit, in oxida
tive and replicative stress responses. Cancer Sci 2009; 100: 1140–55.
12 Saldivar JC, Miuwa S, Bene J et al. Initiation of genome instability and pre-
neoplastic processes through loss of Fhit expression. PLoS Genet 2012; 8: e1003077.
13 Miuwa S, Saldivar JC, Karras JR et al. Fhit deficiency-induced global genome instability promotes mutation and clonal expansion. PLoS ONE 2013; 8: e80730.
14 Waters CE, Saldivar JC, Amin ZA et al. Fhit loss-induced DNA damage creates optimal APOBEC substrates: insights into APOBEC-mediated muta-
genesis. Oncotarget 2015; 6: 3409–19.
15 Burns MB, Leonard B, Harris RS. APOBEC3B: pathological consequences of an innate immune DNA mutator. BioMed J 2015; 38: 102–10.
16 Paisie CA, Schrock MS, Karras JR et al. Exome-wide single-base substitution in tissues and derived cell lines of the constitutive Fhit knockout mouse. Cancer Science 2016; 107: 528–35.
17 Fong LY, Fidanza V, Zanesi N et al. Muir-Torre-like syndrome in Fhit-defi-
cient mice. Proc Natl Acad Sci USA 2000; 97: 4742–7.
18 Guler U, Guler N et al. The fragile genes FHT and WWOX are inactivated coordinately in invasive breast carcinoma. Cancer 2004; 100: 1605–14.
19 Guler U, Barci S, Costinean S et al. Stem cell-related markers in primary breast cancers and associated metastatic lesions. Mod Pathol 2012; 25: 949–55.
20 Iyer S, Spokos M, Hammond M et al. Antitumorogenic effect of Wnt 7a and Fzd 9 in non-small cell lung cancer cells is mediated through ERK-
5-dependent activation of peroxisome proliferator-activated receptor gamma. J Biol Chem 2006; 281: 26943–50.
21 Xing X, Zhang L, Wen X et al. P2Z242 suppresses cell proliferation, meta-
asis, and angiogenesis of gastric cancer through inhibition of the PI3K/AKT/mTOR pathway. Anticancer Drugs 2014; 25: 1129–40.
22 Iseri OD, Sahin FI, Terzi YK et al. beta-Adrenoceptor antagonists reduce cancer cell proliferation, invasion, and migration. Pharm Biol 2014; 52: 1374–81.
23 Guler U, Barci S, Costinean S et al. Stem cell-related markers in primary breast cancers and associated metastatic lesions. Mod Pathol 2012; 25: 949–55.
24 Siprashvili Z, Sozzi G, Barnes LD et al. Replacement of Fhit in cancer cells suppresses tumorigenicity. Proc Natl Acad Sci USA 1997; 94: 13771–6.
25 De Craene B, Bers G. Regulatory networks defining EMT during cancer ini-
tiation and progression. Nat Rev Cancer 2013; 13: 97–110.
26 Alves CC, Carneiro F, Hoeffer H et al. Role of the epithelial–mesenchymal transition regulator Slug in primary human cancers. Front Biosci 2009; 14: 3035–50.
27 Spaderna S, Schmalhofer O, Wahlbuhl M et al. The transcriptional repressor ZEB1 promotes metastasis and loss of cell polarity in cancer. Cancer Res 2008; 68: 537–44.
28 Bao B, Wang Z, Ali S et al. Over-expression of FoxM1 leads to epithelial-
mesenchymal transition and cancer stem cell phenotype in pancreatic cancer cells. J Cell Biochem 2011; 112: 2296–306.
29 Kendler TW, Spira A, Garber JE et al. Transforming cancer prevention through precision medicine and immune-oncology. Cancer Prev Res (Phila) 2016; 9: 2–10.
30 Murphy SJ, Hart SN, Halling GC et al. Integrated genomic analysis of pancreatic ductal adenocarcinomas reveals genomic rearrangement events as sig-
nificant drivers of disease. Cancer Res 2016; 76: 749–61.
31 Hu N, Kadota M, Liu H et al. Genomic landscape of somatic alterations in esophageal squamous cell carcinoma and gastric cancer. Cancer Res 2016; 76: 1714–1723; e-pub ahead of print 8 February 2016; doi: 10.1158/0008-5472.
32 Besler AC, Roniger M, Oren YS et al. Nucleotide deficiency promotes geno-
mic instability in early stages of cancer development. Cell 2011; 145: 435–46.
33 Chabosseau P, Buhagiar-Labarchede G, Onclerc-Delic R et al. Pyrimidine pool imbalance induced by BLM helicase deficiency contributes to genetic instability in Bloom syndrome. Nat Commun 2011; 2: 368.
34 Kumar D, Abdulovic AL, Viberg J et al. Mechanisms of mutagenesis in vivo due to impaired dNTP pools. Nucleic Acids Res 2011; 39: 1360–71.
Table S3. Protein expression changes in Fhit−/− and +/+ kidney cell lines. Expression analysis of proteins at early (p3–16) and late (p40–50) tissue culture passages. ++++, Very strongly expressed; ++, strongly expressed; +, moderately expressed; +/−, faint expression; −, absent.

Table S4. Protein expression in Fhit−/− DMBA survivor (DS), nutritionally stressed (NS), and colony-forming cell lines. ++++, Very strongly expressed; ++, strongly expressed; +, moderately expressed; +/−, faint expression; −, absent.

Fig. S1. Photographs of +/+ and −/− mouse kidney cell lines. Cells were examined by light and phase-contrast microscopy. Classic epithelial morphology is observed in +/+ and −/− lines at early and late passages. NS lines and NS3T show a mesenchymal phenotype where cells are less cuboidal and more elongated in shape.

Fig. S2. Proliferation assay of +/+ and −/− mouse kidney cell lines. Cells (1 × 10⁵) of each cell line were plated in duplicate. Cells were counted using TC20 Automated Cell Counter (Bio-Rad) at 4, 8, 12, 24, and 48 h after plating. Error bars indicate SE at each time point for three independent experiments. Growth kinetics for early and late passage wt kd3 cell lines were not significantly different (48 h; P = 0.07). At 48 h, the −/− kd3 p11 cells showed growth kinetics similar to wt cells (P = 0.241); however, a significant increase in growth kinetics of −/−kd3 p53 was observed (P = 0.014). NS, not significant.

Fig. S3. Chromatogram of Trp53 sequences in NS cell lines. Heterozygous C>G mutation at amino acid position 151 in NS2 cells, changing a serine to an arginine; homozygous C>G mutation at amino acid position 131 for NS1, NS3, and NS4 cells, changing a phenylalanine to a leucine.

Fig. S4. Mesenchymal spindle cell neoplasm phenotype of NS3 colony tumors. NS3 colony cells were injected s.c. into the flank and shoulder of one male nude mouse. Both sites developed tumors that show a histological phenotype consistent with a mesenchymal spindle cell neoplasm. All masses are unencapsulated and composed of mesenchymal spindle cells on a fine fibrovascular, with distinct collagen fibrils between individual neoplastic cells. Multinucleated cells are also prominent.